Nektar Therapeutics [NASDAQ: NKTR] stock went on an upward path that rose over 6.98% on Wednesday, amounting to a one-week price increase of more than 6.15%.
Over the last 12 months, NKTR stock rose by 161.86%. The one-year Nektar Therapeutics stock forecast points to a potential upside of 43.21. The average equity rating for NKTR stock is currently 3.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $254.03 million, with 191.38 million shares outstanding and 177.81 million shares in the current float. Compared to the average trading volume of 977.36K shares, NKTR stock reached a trading volume of 3904926 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Nektar Therapeutics [NKTR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $2.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 30, 2024. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on June 28, 2024, representing the official price target for Nektar Therapeutics stock.
The Average True Range (ATR) for Nektar Therapeutics is set at 0.09, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 2.73. The Price to Book ratio for the last quarter was 3.19, with the Price to Cash per share for the same quarter was set at 1.47.
NKTR Stock Performance Analysis:
Nektar Therapeutics [NKTR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.15. With this latest performance, NKTR shares gained by 6.15% in over the last four-week period, additionally plugging by 2.22% over the last 6 months – not to mention a rise of 161.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 59.08, with the RSI for the last a single of trading hit 62.52, and the three-weeks RSI is set at 56.56 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 1.2495, while it was recorded at 1.3280 for the last single week of trading, and 1.1408 for the last 200 days.
Insight into Nektar Therapeutics Fundamentals:
Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 5.15.
NKTR Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.
Nektar Therapeutics [NKTR] Institutonal Ownership Details
There are presently around $74.01%, or 74.80%% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: DEEP TRACK CAPITAL, LP with ownership of 17.88 million shares, which is approximately 9.1789%. BLACKROCK INC., holding 15.16 million shares of the stock with an approximate value of $$18.79 million in NKTR stocks shares; and BLACKROCK INC., currently with $$16.08 million in NKTR stock with ownership which is approximately 6.6587%.
